Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operationsBRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Largest ever protein study set to revolutionise cancer and dementia tests - Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

UBS has recently raised AstraZeneca PLC (AZN) stock to Neutral rating, as announced on November 20, 2024, according to Finviz. Earlier, on November 6, 2024, Deutsche Bank had raised the stock from a ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...